These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 25589778)

  • 21. Rifampin greatly reduces the plasma concentrations of intravenous and oral oxycodone.
    Nieminen TH; Hagelberg NM; Saari TI; Pertovaara A; Neuvonen M; Laine K; Neuvonen PJ; Olkkola KT
    Anesthesiology; 2009 Jun; 110(6):1371-8. PubMed ID: 19417618
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is saliva a valid substitute for plasma in pharmacokinetic studies of oxycodone and its metabolites in patients with cancer?
    Hardy J; Norris R; Anderson H; O'Shea A; Charles B
    Support Care Cancer; 2012 Apr; 20(4):767-72. PubMed ID: 21491207
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of oxycodone pharmacokinetics after buccal and sublingual administration in children.
    Kokki H; Rasanen I; Lasalmi M; Lehtola S; Ranta VP; Vanamo K; Ojanperä I
    Clin Pharmacokinet; 2006; 45(7):745-54. PubMed ID: 16802855
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Randomized, double-blind, placebo-controlled study of the abuse potential of different formulations of oral oxycodone.
    Webster LR; Bath B; Medve RA; Marmon T; Stoddard GJ
    Pain Med; 2012 Jun; 13(6):790-801. PubMed ID: 22568663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Screening postmortem whole blood for oxycodone by ELISA response ratios.
    Spiehler VR; DeCicco L; McCutcheon JR; Kupiec T; Kemp P
    J Forensic Sci; 2004 May; 49(3):621-6. PubMed ID: 15171187
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Performance characteristics of the Cozart RapiScan Oral Fluid Drug Testing System for opiates in comparison to ELISA and GC/MS following controlled codeine administration.
    Kacinko SL; Barnes AJ; Kim I; Moolchan ET; Wilson L; Cooper GA; Reid C; Baldwin D; Hand CW; Huestis MA
    Forensic Sci Int; 2004 Apr; 141(1):41-8. PubMed ID: 15066713
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of oral oxycodone in healthy human subjects: role of circulating active metabolites.
    Lalovic B; Kharasch E; Hoffer C; Risler L; Liu-Chen LY; Shen DD
    Clin Pharmacol Ther; 2006 May; 79(5):461-79. PubMed ID: 16678548
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Urine drug testing of chronic pain patients. II. Prevalence patterns of prescription opiates and metabolites.
    Heltsley R; Zichterman A; Black DL; Cawthon B; Robert T; Moser F; Caplan YH; Cone EJ
    J Anal Toxicol; 2010; 34(1):32-8. PubMed ID: 20109300
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of blocking CYP2D6 on the pharmacokinetics and pharmacodynamics of oxycodone.
    Heiskanen T; Olkkola KT; Kalso E
    Clin Pharmacol Ther; 1998 Dec; 64(6):603-11. PubMed ID: 9871425
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low-level quantitation of oxycodone and its oxidative metabolites, noroxycodone, and oxymorphone, in rat plasma by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry.
    Edwards SR; Smith MT
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Apr; 848(2):264-70. PubMed ID: 17098487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Should the dosage of controlled-release oxycodone in advanced cancer be modified on the basis of patient characteristics?
    Charles B; Hardy J; Anderson H; Tapuni A; George R; Norris R
    Support Care Cancer; 2014 Feb; 22(2):325-30. PubMed ID: 24077699
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Retrospective Analysis of Selected Opioids in Hair of Workplace Drug Testing Subjects.
    Stowe GN; Paulsen RB; Hill VA; Schaffer MI
    J Anal Toxicol; 2019 Aug; 43(7):553-563. PubMed ID: 31009051
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The pharmacokinetics of oxycodone and its metabolites following single oral doses of Remoxy®, an abuse-deterrent formulation of extended-release oxycodone, in patients with hepatic or renal impairment.
    Malhotra BK; Schoenhard GL; de Kater AW; Friedmann N
    J Opioid Manag; 2015; 11(2):157-69. PubMed ID: 25901481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determination of oxycodone, noroxycodone and oxymorphone by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry in human matrices: in vivo and in vitro applications.
    Fang WB; Lofwall MR; Walsh SL; Moody DE
    J Anal Toxicol; 2013; 37(6):337-44. PubMed ID: 23743505
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Contribution of oxycodone and its metabolites to the overall analgesic effect after oxycodone administration.
    Klimas R; Witticke D; El Fallah S; Mikus G
    Expert Opin Drug Metab Toxicol; 2013 May; 9(5):517-28. PubMed ID: 23488585
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positivity rates of drugs in patients treated for opioid dependence with buprenorphine: A comparison of oral fluid and urine using paired collections and LC-MS/MS.
    West R; Mikel C; Hofilena D; Guevara M
    Drug Alcohol Depend; 2018 Dec; 193():183-191. PubMed ID: 30391868
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The U.S. Mandatory Guidelines for Federal Workplace Drug Testing Programs: current status and future considerations.
    Bush DM
    Forensic Sci Int; 2008 Jan; 174(2-3):111-9. PubMed ID: 17434274
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design and in vivo evaluation of oxycodone once-a-day controlled-release tablets.
    Kim JY; Lee SH; Park CW; Rhee YS; Kim DW; Park J; Lee M; Seo JW; Park ES
    Drug Des Devel Ther; 2015; 9():695-706. PubMed ID: 25678774
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of oxycodone/naloxone and its metabolites in patients with end-stage renal disease during and between haemodialysis sessions.
    Leuppi-Taegtmeyer A; Duthaler U; Hammann F; Schmid Y; Dickenmann M; Amico P; Jehle AW; Kalbermatter S; Lenherr C; Meyer Zu Schwabedissen HE; Haschke M; Liechti ME; Krähenbühl S
    Nephrol Dial Transplant; 2019 Apr; 34(4):692-702. PubMed ID: 30189012
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of physical manipulation on in vitro and in vivo release profiles of oxycodone DETERx®: an extended-release, abuse-deterrent formulation.
    Kopecky EA; Fleming AB; Noonan PK; Varanasi RK; Grima M; Saim S; Mayock SP
    J Opioid Manag; 2014; 10(4):233-46. PubMed ID: 25162603
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.